The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.

Ponikowski, Piotr; Filippatos, Gerasimos; Comín Colet, Josep; Willenheimer, Ronnie; Dickstein, Kenneth; Lüscher, Thomas F.; Gaudesius, Giedrius; von Eisenhart Rothe, Barbara; Mori, Claudio; Greenlaw, Nicola; Ford, Ian; Macdougall, Iain; Anker, Stefan D.; FAIR-HF Trial Investigators

The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.

Mostra el registre complet Registre parcial de l'ítem

dc.contributor.author Ponikowski, Piotrca
dc.contributor.author Filippatos, Gerasimosca
dc.contributor.author Comín Colet, Josepca
dc.contributor.author Willenheimer, Ronnieca
dc.contributor.author Dickstein, Kennethca
dc.contributor.author Lüscher, Thomas F.ca
dc.contributor.author Gaudesius, Giedriusca
dc.contributor.author von Eisenhart Rothe, Barbaraca
dc.contributor.author Mori, Claudioca
dc.contributor.author Greenlaw, Nicolaca
dc.contributor.author Ford, Ianca
dc.contributor.author Macdougall, Iainca
dc.contributor.author Anker, Stefan D.ca
dc.contributor.author FAIR-HF Trial Investigatorsca
dc.date.accessioned 2016-04-19T10:26:46Z
dc.date.available 2016-04-19T10:26:46Z
dc.date.issued 2015
dc.description.abstract AIMS: Anaemia and iron deficiency are constituents of the cardio-renal syndrome in chronic heart failure (CHF). We investigated the effects of i.v. iron in iron-deficient CHF patients on renal function, and the efficacy and safety of this therapy in patients with renal dysfunction. METHODS AND RESULTS: The FAIR-HF trial randomized 459 CHF patients with iron deficiency (ferritin <100 µg/L, or between 100 and 299 µg/L if transferrin saturation was <20%): 304 to i.v. ferric carboxymaltose (FCM) and 155 to placebo, and followed-up for 24 weeks. Renal function was assessed at baseline and at weeks 4, 12, and 24, using the estimated glomerular filtration rate (eGFR, mL/min/1.73 m(2) ), calculated from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. At baseline, renal function was similar between groups (62.4 ± 20.6 vs. 62.9 ± 23.4 mL/min/1.73 m(2) , FCM vs. placebo). Compared with placebo, treatment with FCM was associated with an increase in eGFR [treatment effect: week 4, 2.11 ± 1.21 (P = 0.082); week 12, 2.41 ± 1.33 (P = 0.070); and week 24, 2.98 ± 1.44 mL/min/1.73 m(2) (P = 0.039)]. This effect was seen in all pre-specified subgroups (P > 0.20 for interactions). No interaction between the favourable effects of FCM and baseline renal function was seen for the primary endpoints [improvement in Patient Global Assessment (P = 0.43) and NYHA class (P = 0.37) at 24 weeks]. Safety and adverse event profiles were similar in patients with baseline eGFR <60 and ≥60 mL/min/1.73 m(2) . CONCLUSIONS: Treatment of iron deficiency in CHF patients with i.v. FCM was associated with an improvement in renal function. FCM therapy was effective and safe in CHF patients with renal dysfunction.ca
dc.description.sponsorship The FAIR-HF study and this analysis were supported by Vifor Pharma, Zurich, Switzerland.
dc.format.mimetype application/pdfca
dc.identifier.citation Ponikowski P, Filippatos G, Colet JC, Willenheimer R, Dickstein K, Lüscher T. et al. The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study. Eur J Heart Fail. 2015 Mar;17(3):329-39. doi: 10.1002/ejhf.229.ca
dc.identifier.doi http://dx.doi.org/10.1002/ejhf.229
dc.identifier.issn 1388-9842
dc.identifier.uri http://hdl.handle.net/10230/26121
dc.language.iso engca
dc.publisher Oxford University Pressca
dc.relation.ispartof European Journal of Heart Failure. 2015 Mar;17(3):329-39
dc.rights ©2015 The Authors.European Journal of Heart Failurepublished by John Wiley & Sons Ltd on behalf of European Society of Cardiology.This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/, which permits use anddistribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.ca
dc.rights.accessRights info:eu-repo/semantics/openAccessca
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/ca
dc.subject.other Insuficiència cardíacaca
dc.subject.other Aparell urinari -- Fisiologiaca
dc.title The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.ca
dc.type info:eu-repo/semantics/articleca
dc.type.version info:eu-repo/semantics/publishedVersionca

Col·leccions

Articles (Hospital del Mar Research Institute)